All In Biotech

Drug Trial Radar · NCT05864014

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

213

Actual

Start

Apr 25, 2023

Primary completion

Mar 3, 2025

Study completion Sep 2025

Sponsor

Sponsor type
Industry
First posted
May 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.

Conditions

  • Chemotherapy-Induced Thrombocytopenia

Interventions

  • HetrombopagDrug

    Hetrombopag

  • Hetrombopag plus PlaceboDrug

    Hetrombopag plus Placebo

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of treatment responders.Time frame: Randomization up to 80 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hematology Tumor Research Center of Harbin First Hospital

    Haerbin, Heilongjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.